Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) (NCT05733689)
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) - a Phase Ib Feasibility Trial
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a response-guided approach to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal junction (GEA).
Who can join: Review the eligibility criteria below.
Location: Chao Family Comprehensive Cancer Center, University — Orange, California
Age range: 18 Years
🧪 Interventions in This Study
- FLOT (COMBINATION_PRODUCT)
- FOLFOX (COMBINATION_PRODUCT)
- FOLFIRI (COMBINATION_PRODUCT)
- FOLFIRINOX (COMBINATION_PRODUCT)
- PACLITAXEL with or without CARBOPLATIN (COMBINATION_PRODUCT)
- DOCETAXEL and IRINOTECAN (alone or combined) (COMBINATION_PRODUCT)
- NIVOLUMAB (alone or when added to a regimen above) (DRUG)
- PEMBROLIZUMAB (alone or when added to a regimen above) (DRUG)
- Durvalumab (DRUG)
- Trastuzumab (DRUG)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Chao Family Comprehensive Cancer Center, University — Orange, California
📞 Contact the Study Coordinator
Phone: (877) 827-8839
Email: ucstudy@uci.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastroesophageal Adenocarcinoma
- Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) — Tampa, Florida
- RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial — Montreal,
- AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas — Los Angeles, California
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma — Newark, Delaware
- Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma — Calgary, Alberta
Explore by condition: All Gastroesophageal Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.